 Connection
Susana Arrigain to Proportional Hazards Models
This is a "connection" page, showing publications Susana Arrigain has written about Proportional Hazards Models.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.468 |
|
|
|
-
Lehr CJ, Schold JD, Arrigain S, Valapour M. New OPTN/UNOS data demonstrates higher than previously reported waitlist mortality for lung transplant candidates supported with ECMO. J Heart Lung Transplant. 2023 10; 42(10):1399-1407.
Score: 0.043
-
Cholin L, Ashour T, Mehdi A, Taliercio JJ, Daou R, Arrigain S, Schold JD, Thomas G, Nally J, Nakhoul NL, Nakhoul GN. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol. 2021 07 15; 22(1):264.
Score: 0.038
-
Azem R, Daou R, Bassil E, Anvari EM, Taliercio JJ, Arrigain S, Schold JD, Vachharajani T, Nally J, Na Khoul GN. Serum magnesium, mortality and disease progression in chronic kidney disease. BMC Nephrol. 2020 02 12; 21(1):49.
Score: 0.034
-
Saeed F, Arrigain S, Schold JD, Nally JV, Navaneethan SD. What are the Risk Factors for One-Year Mortality in Older Patients with Chronic Kidney Disease? An Analysis of the Cleveland Clinic CKD Registry. Nephron. 2019; 141(2):98-104.
Score: 0.031
-
Navaneethan SD, Schold JD, Walther CP, Arrigain S, Jolly SE, Virani SS, Winkelmayer WC, Nally JV. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol. 2018 Jul - Aug; 12(4):1061-1071.e7.
Score: 0.030
-
Rincon-Choles H, Jolly SE, Arrigain S, Konig V, Schold JD, Nakhoul G, Navaneethan SD, Nally JV, Rothberg MB. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol. 2017; 46(4):315-322.
Score: 0.029
-
Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Blum MF, Winkelmayer WC, Nally JV. Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease. Kidney Int. 2017 11; 92(5):1272-1281.
Score: 0.029
-
Navaneethan SD, Schold JD, Huang H, Nakhoul G, Jolly SE, Arrigain S, Dweik RA, Nally JV. Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease. Am J Nephrol. 2016; 43(1):39-46.
Score: 0.026
-
Navaneethan SD, Schold JD, Arrigain S, Kirwan JP, Nally JV. Body mass index and causes of death in chronic kidney disease. Kidney Int. 2016 Mar; 89(3):675-82.
Score: 0.026
-
Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV, Navaneethan SD. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol. 2015 Jul 07; 10(7):1119-27.
Score: 0.025
-
Toledo C, Thomas G, Schold JD, Arrigain S, Gornik HL, Nally JV, Navaneethan SD. Renal resistive index and mortality in chronic kidney disease. Hypertension. 2015 Aug; 66(2):382-8.
Score: 0.025
-
Navaneethan SD, Sakhuja A, Arrigain S, Sharp J, Schold JD, Nally JV. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease. Clin Nephrol. 2014 Jul; 82(1):16-25.
Score: 0.023
-
Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, Beddhu S, Nally JV. Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol. 2013 Jun; 8(6):945-52.
Score: 0.021
-
Navaneethan SD, Schold JD, Arrigain S, Thomas G, Jolly SE, Poggio ED, Schreiber MJ, Sarnak MJ, Nally JV. Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease. Nephrol Dial Transplant. 2012 Aug; 27(8):3228-34.
Score: 0.020
-
Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Wehbe E, Raina R, Simon JF, Srinivas TR, Jain A, Schreiber MJ, Nally JV. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2395-402.
Score: 0.019
-
Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ, Simon JF, Srinivas TR, Nally JV. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis. 2011 Oct; 58(4):536-43.
Score: 0.019
-
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009 Jun; 46(2):145-54.
Score: 0.016
-
Wells BJ, Jain A, Arrigain S, Yu C, Rosenkrans WA, Kattan MW. Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care. 2008 Dec; 31(12):2301-6.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|